303 related articles for article (PubMed ID: 20118772)
21. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
[TBL] [Abstract][Full Text] [Related]
22. The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors.
Ploeckinger U; Kloeppel G; Wiedenmann B; Lohmann R;
Neuroendocrinology; 2009; 90(4):349-63. PubMed ID: 19776553
[TBL] [Abstract][Full Text] [Related]
23. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder.
Bol MG; Baak JP; Buhr-Wildhagen S; Kruse AJ; Kjellevold KH; Janssen EA; Mestad O; Øgreid P
J Urol; 2003 Apr; 169(4):1291-4. PubMed ID: 12629345
[TBL] [Abstract][Full Text] [Related]
24. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling.
López-Bonet E; Alonso-Ruano M; Barraza G; Vazquez-Martin A; Bernadó L; Menendez JA
Oncol Rep; 2008 Dec; 20(6):1369-74. PubMed ID: 19020716
[TBL] [Abstract][Full Text] [Related]
25. Natural history, clinicopathologic classification and prognosis of gastric ECL cell tumors.
Solcia E; Rindi G; Paolotti D; Luinetti O; Klersy C; Zangrandi A; La Rosa S; Capella C
Yale J Biol Med; 1998; 71(3-4):285-90. PubMed ID: 10461359
[TBL] [Abstract][Full Text] [Related]
26. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry.
Bellizzi AM
Adv Anat Pathol; 2013 Sep; 20(5):285-314. PubMed ID: 23939147
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in mesothelioma staging.
Richards WG
Semin Thorac Cardiovasc Surg; 2009; 21(2):105-10. PubMed ID: 19822281
[TBL] [Abstract][Full Text] [Related]
28. The molecular genetics of gastroenteropancreatic neuroendocrine tumors.
Zikusoka MN; Kidd M; Eick G; Latich I; Modlin IM
Cancer; 2005 Dec; 104(11):2292-309. PubMed ID: 16258976
[TBL] [Abstract][Full Text] [Related]
29. [The Montreal definition and classification of gastroesophageal reflux disease: a global, evidence-based consensus paper].
Vakil N; van Zanten SV; Kahrilas P; Dent J; Jones R;
Z Gastroenterol; 2007 Nov; 45(11):1125-40. PubMed ID: 18027314
[TBL] [Abstract][Full Text] [Related]
30. Delphi process yielded consensus on terminology and research agenda for therapeutic footwear for neuropathic foot.
Dahmen R; van der Wilden GJ; Lankhorst GJ; Boers M
J Clin Epidemiol; 2008 Aug; 61(8):819-26. PubMed ID: 18378426
[TBL] [Abstract][Full Text] [Related]
31. The pathology of bladder cancer: An update on selected issues.
Pavone-Macaluso M; Lopez-Beltran A; Aragona F; Bassi P; Fitzpatrick JM
BJU Int; 2006 Dec; 98(6):1161-5. PubMed ID: 16879435
[TBL] [Abstract][Full Text] [Related]
32. [Liver metastases from neuroendocrine tumours of the gastroenteropancreatic system--therapeutic strategies].
Auernhammer CJ; Jauch KW; Hoffmann JN
Zentralbl Chir; 2009 Sep; 134(5):410-7. PubMed ID: 19757340
[TBL] [Abstract][Full Text] [Related]
33. [Classification of broncho-pulmonary cancers (WHO 1999)].
Brambilla E
Rev Mal Respir; 2002 Sep; 19(4):455-66. PubMed ID: 12417862
[TBL] [Abstract][Full Text] [Related]
34. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
35. [Neuroendocrine tumors of digestive system: morphologic spectrum and cell proliferation (Ki67 index)].
Delektorskaia VV; Kushliskiĭ NE
Vestn Ross Akad Med Nauk; 2013; (5):28-37. PubMed ID: 24000665
[TBL] [Abstract][Full Text] [Related]
36. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.
Shimada H; Ambros IM; Dehner LP; Hata J; Joshi VV; Roald B
Cancer; 1999 Jul; 86(2):349-63. PubMed ID: 10421272
[TBL] [Abstract][Full Text] [Related]
37. The frequency and clinical significance of neuroendocrine cells within stage III adenocarcinomas of the colon.
Foley EF; Gaffey MJ; Frierson HF
Arch Pathol Lab Med; 1998 Oct; 122(10):912-4. PubMed ID: 9786353
[TBL] [Abstract][Full Text] [Related]
38. [Ki67 and neuroendocrine tumors].
Couvelard A
Ann Pathol; 2011 Nov; 31(5 Suppl):S55-6. PubMed ID: 22054461
[No Abstract] [Full Text] [Related]
39. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.
Strosberg J; Nasir A; Coppola D; Wick M; Kvols L
Hum Pathol; 2009 Sep; 40(9):1262-8. PubMed ID: 19368957
[TBL] [Abstract][Full Text] [Related]
40. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
